Trial intelligence / Profile preview

Molecular Profiling for Neoadjuvant Therapy in Pancreatic Cancer

NCT01726582Phase 2Completed

Sponsor
Medical College of Wisconsin
Start
Nov 2011
Primary completion
Jun 2018
Modality
DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
Countries
1
01

Overview

A Phase 2 trial of fluorouracil, irinotecan, oxaliplatin, gemcitabine, cisplatin in pancreatic adenocarcinoma (PDAC), sponsored by Medical College of Wisconsin. Started Nov 2011; status: completed.

02

Drugs

fluorouracilirinotecanoxaliplatingemcitabinecisplatin
03

Conditions

pancreatic adenocarcinoma (PDAC)

Beyond the preview

Go deeper on NCT01726582.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01726582.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call